Double Wood NMN 99% Purity Tested Review

On sticker price, yes — it's the lowest-priced pick in this nine-product lineup at roughly $20, from a well-known, widely-reviewed value brand. That's its whole reason for being: the cheapest credible way to try NMN before committing to a premium product. The nuance is that the 250 mg serving takes two capsules, so a 60-capsule bottle lasts 30 days, and the per-serving dose is lower than the 500 mg single-capsule options like Partiqlar (#4). On a pure cost-per-gram basis a larger-dose bottle can close the gap, but for a first-time buyer who simply wants a low total outlay to test the category, Double Wood is the obvious starting point.

The brand states 99% purity, independently verified, with no fillers — but the listing does not assert a named independent certifier seal such as NSF or USP, so we record testing as "None stated" rather than upgrading the claim. "Independently verified" is a brand statement, not a third-party certification mark we can point to. That's the honest standard we apply across this lineup: only Elysium Basis (#6, NSF Certified for Sport) and Tru Niagen (#2, ISO/IEC-accredited batch testing) carry genuine independent-certification claims. For a value pick, Double Wood's brand-stated purity and long track record are the reassurance on offer.

Each capsule contains 125 mg of NMN, so reaching the 250 mg serving means taking two. There's a small upside to that: the 125 mg-per-capsule format lets a newcomer titrate — start with one capsule at 125 mg and work up — which is a sensible way to introduce a new supplement. The downside is that a 60-capsule bottle is only a 30-day supply at the full serving, and 250 mg is a lower per-serving dose than the 500 mg single-capsule picks. If you want a higher dose in fewer capsules, Partiqlar (#4) delivers 500 mg in one veggie capsule.

Different priorities. ProHealth (#1) is the credibility-forward best-overall pick — branded, clinically-studied Uthever NMN at 500 mg with triple lab testing, at a premium price. Partiqlar (#4) is the value standout among serious single-ingredient NMN: 500 mg per capsule, brand-stated >99% purity, 60-count, at one of the better cost-per-gram profiles. Double Wood undercuts both on sticker price and comes from a trusted value brand, but at a lower 250 mg/2-capsule serving with brand-stated (not branded-raw-material or independently-certified) purity. Choose Double Wood to try the category cheaply; choose Partiqlar or ProHealth if you want a higher single-capsule dose or a more credibility-forward formulation.

No — treat it as a low-cost experiment, not a longevity guarantee. This applies to every NMN product, regardless of price: the human evidence is early and mixed. Small trials show oral NMN can raise blood NAD+ and may modestly help surrogate markers like muscle insulin sensitivity, but there is no good evidence it extends human lifespan or reverses aging. Double Wood's appeal is that it lets you test NMN at the lowest entry cost; that's the right frame — a cheap way to run the experiment in your own metabolism with realistic expectations.

1. [1] Yoshino 2021 PMID 33888596 — Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. In a randomized, placebo-controlled, double-blind trial, 10 weeks of oral NMN (250 mg/day) in postmenopausal women with prediabetes increased muscle insulin sensitivity versus placebo. The most-cited human efficacy signal for NMN — but a surrogate metabolic marker in a small cohort, not evidence of extended lifespan, regardless of brand or price.
2. [2] Irie 2020 PMID 31685720 — Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. A first-in-human study giving single oral doses of NMN (100, 250, 500 mg) to 10 healthy men found it was safely metabolized with no significant deleterious effects and raised nicotinamide metabolite levels dose-dependently. Establishes basic human safety and bioavailability — a single-dose pharmacokinetic study, not an efficacy or longevity trial.
3. [3] Fukamizu 2022 PMID 36002548 — Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. A randomized, placebo-controlled trial found oral β-NMN at up to 1,250 mg/day for 4 weeks was safe and well tolerated in healthy adults. Supports the tolerability of NMN at a range of doses — but it is a safety study, not evidence that any dose, low or high, produces a longevity benefit.